Table 3.

Existing guidelines regarding subsequent treatment after atezolizumab-bevacizumab combination.

	Second-Line Options	Further-Line Options
BCLC [3]	Clinical trials
EASL [44]	Multi-TKI and VEGFR2 inhibitor as per off-label availability
ILCA, https://ilca-online.org/education/ilca-guidances/ (accessed on 24 November 2022)	sorafenib, lenvatinib, cabozantinib	regorafenib
NCCN preferred treatments	sorafenib, lenvatinib, regorafenib, cabozantinib, ramucirumab
ESMO https://www.esmo.org/guidelines/gastrointestinal-cancers/hepatocellular-carcinoma (accessed on 24 November 2022)	sorafenib, lenvatinib, cabozantinib, ramucirumab	regorafenib (for TKI-experienced patients)
French recommendation (TNCD)	sorafenib, lenvatinib	regorafenib, cabozantinib, ramucirumab